The broker is feeling very bullish about the sleep disorder treatment company. The post Goldman Sachs tips ResMed shares to ...

The stock's rise snapped a four-day losing streak.

Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.

Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...

Shares of ResMed Inc. RMD slumped 0.62% to $228.83 Tuesday, on what proved to be an all-around favorable trading session for ...

Signal Advisors Wealth LLC increased its stake in ResMed Inc. (NYSE:RMD – Free Report) by 6.1% in the 4th quarter, according ...

Adam Maeder, an analyst from Piper Sandler, has initiated a new Hold rating on Resmed (RMD).Stay Ahead of the Market:Discover outperforming ...

Shares of ResMed Inc. (NYSE:RMD – Get Free Report) have earned a consensus rating of “Hold” from the thirteen brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst ...

ResMed (RMD) is on the list of such stocks currently recommended by our proprietary system. In addition to a favorable Growth Score, it carries a top Zacks Rank. Research shows that stocks carrying ...

Chipotle Mexican Grill owns and operates Chipotle Mexican Grill restaurants. The company’s expected earnings growth rate for ...

Goldman Sachs has a buy rating and $36.20 price target on Woolworths' shares. Analysts at Catapult Wealth are positive on ...